Clinical trials located in

Roeselare

Roeselare city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Roeselare, located in the Flemish province of West Flanders, Belgium, is a city rich in history and culture. Known for its vibrant cycling scene, it is home to the National Cycling Museum, celebrating Belgium’s deep-rooted cycling heritage. The city’s architecture is a blend of modern and historical, with the Saint Michael’s Church being a notable landmark. Roeselare also played a significant role in the linen and textile industry, contributing to its economic growth. Additionally, it has a strong connection to Rodenbach beer, a unique sour ale that is part of the city’s proud brewing tradition.

  • CT-EU-00120106

    Study of Elafibranor in the treatment of adult patients with Primary Biliary Cholangitis (PBC)

    The clinical trial is aimed at adult patients with confirmed primary cholangitis (PBC). Patients with this condition have an inadequate response or intolerance to ursodeoxycholic acid (UDCA), a drug used to treat PBC.

    Primary cholangitis is a disease that slowly progresses and leads to damage to the bile ducts in the liver. This causes a build-up of bile acids, which further damages the liver. As the disease progresses, scarring of the liver may develop (cirrhosis). PBC is also associated with numerous symptoms, such as itching and fatigue, and may lead to the need for a liver transplant.

    The study evaluates the effectiveness and safety of a drug called elafibranor at a dose of 80 mg daily. The study will compare elafibranor with a placebo, an inactive substance administered for control purposes. The main goal of the study is to test the effectiveness of elafibranor. The safety of long-term use of this medicine and its effect on symptoms such as itching and fatigue will also be checked.

    • Elafibranor
  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Treatment of lung cancer before and after surgery using various drug combinations

    The NeoCOAST-2 trial is a phase II study evaluating various combinations of anticancer therapies in patients with resectable early-stage non-small cell lung cancer. This study is divided into two stages. The first stage occurs before surgery (neoadjuvant treatment), the next stage after surgery (adjuvant treatment). Researchers will use a drug called Durvalumab, which will be combined with various drugs. The goal is to determine the safety and effectiveness of these regimens for treating early-stage lung cancer, potentially improving treatment outcomes.

    The first group of patients will receive Oleclumab, Durvalumab and a strong drug – Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin. After surgery, they will be given Oleclumab and Durvalumab.

    Patients in the second group will receive Monalizumab, Durvalumab and drugs combined with platinum before surgery. After surgery, they will be given Monalizumab and Durvalumab.

    In the third group, MEDI5752 and drugs combined with platinum are administered before surgery. After surgery, patients will only receive MEDI5752.

    People from group four receive Dato-DXd, Durvalumab, Carboplatin or Cisplatin before surgery. After surgery, they will be given Durvalumab.

    Participants in the fifth group will receive AZD0171, Durvalumab and platinum doublet chemotherapy before surgery. After surgery, patients will receive AZD0171 and Durvalumab.

    • AZD0171- new potential medication for advanced cancer
    • Oleclumab
    • Monalizumab
    • MEDI5752
    • Dato-DXd
    • Pemetrexed
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Durvalumab
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    • Luspatercept
  • Study on sonrotoclax’s effects on returning mantle cell lymphoma

    In this medical trial, doctors are studying the effects of a medication, sonrotoclax (BGB-11417), on people suffering from a type of hard-to-treat blood cancer known as mantle cell lymphoma, which has come back or has not responded to previous treatments. The study is divided into two sections. In the first part, doctors will focus on finding how safe and tolerable this new drug is, the highest dose one can safely take, and the best dose for phase 2 studies. In the second part, they will study how effectively this medicine can treat the cancer at the best dose found in part one. The trial offers hope for better outcomes by exploring this new therapy option, aiming to improve the quality of life for patients facing this challenging condition.

    • BGB-11417/Sonrotoclax
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Study on effective dose of new potential drug for Leukemia or myelodysplastic syndrome treatment

    In this study, patients with a type of blood cancer, either Acute Myeloid Leukemia or Myelodysplastic Syndrome that has recurred or not responded to previous treatment, will be administered a new drug named CYAD-02. The initial phase of the study aims to determine the safe dosage of CYAD-02 for patients. Before receiving CYAD-02, patients will undergo a milder form of chemotherapy termed non-myeloablative preconditioning.

    The testing process is divided into three stages, each involving different doses of CYAD-02. The first CYAD-02 treatment will be administered after three consecutive days of chemotherapy. For patients showing stability, additional CYAD-02 treatments may be provided without preceding light chemotherapy. All patients who have received at least one CYAD-02 treatment will be monitored for approximately 15 years.

    • CYAD-02
    • ENDOXAN
    • Fludara
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Research on new medicine for advanced or metastatic lung cancer

    This study investigates a new medicine called JDQ443’s ability to combat advanced non-small cell lung cancer. It involves two groups based on their PD-L1 levels and mutations KRAS G12C. The study has two parts (called cohorts), each involving different people. The study is carried out in stages called ‘cycles’ which last for 21 days each. During the study, assessments will be conducted to evaluate the medicine’s effectiveness, and health monitoring will be implemented. This involves measuring factors such as the duration until disease progression and the length of survival post-treatment initiation.

    • Opnurasib/JDQ-443
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • Comparing tarlatamab and standard therapy in recurring small cell lung cancer

    The study is a trial comparing tarlatamab, a new therapy, with standard care for Small Cell Lung Cancer (SCLC) patients who’ve had platinum-based chemotherapy. It aims to improve survival rates and assesses the drug’s safety and effectiveness in about 700 people. Participants will either receive tarlatamab or standard treatments like lurbinectedin, topotecan, or amrubicin. The main goal is to see if tarlatamab can extend patients’ lives compared to usual treatments. The study also monitors health-related quality of life, treatment response, and safety.

    • Amrubicin
    • Tarlatamab
    • topotecan
    • Lurbinectedin
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    • Navitoclax
    • Ruxolitinib
  • Testing new therapies for extensive stage small cell lung cancer

    In this study, researchers are investigating the new medication Tarlatamab for individuals diagnosed with Extensive Stage Small Cell Lung Cancer, a form of lung cancer that has spread widely. tarlatamab is administered in combination with other chemotherapies, specifically carboplatin and etoposide, along with a PD-L1 inhibitor. The primary focus of the study is to assess the safety of tarlatamab and to identify any potential side effects associated with this new treatment approach.

    • Tarlatamab
    • Etoposide
    • Atezolizumab
    • Carboplatin
    • Durvalumab
  • Inupadenant study in second-line non-small cell lung cancer

    This clinical trial aims to explore the potential of inupadenant (EOS100850) when combined with standard chemotherapy drugs, carboplatin and pemetrexed, in treating advanced non-small cell lung cancer in adults. The study is particularly focused on patients for whom previous immunotherapy treatments were not successful.

    The trial has two primary goals. Initially, it seeks to determine the most effective and safest dose of inupadenant when used alongside chemotherapy. Once the optimal dosage is established, the next phase involves comparing the treatment’s effectiveness against a placebo, in combination with the chemotherapy drugs.

    Throughout the study, participants’ health and responses to the treatment are closely monitored.

    • inupadenant
    • Pemetrexed
    • Carboplatin
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian

See more clinical trials in other cities in Belgium:

.